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A B S T R A C T
Introduction: Infective endocarditis (IE) has high mortality, partly due to delayed diagnosis. No biomarker
can identify IE in patients with fever and clinical picture of infection. To find putative biomarkers we
analyzed serum levels of two proteins found in cardiac valves, fibulin-1 (n = 696) and osteoprotegerin
(n = 689) among patients on clinical suspicion of IE. Proteomic analyses were performed in 24 patients
with bacteremia, 12 patients with definite IE and 12 patients with excluded IE.
Methods: Fibulin-1 and osteoprotegerin were studied by enzyme linked immunosorbent assay (ELISA).
Proteomic analyses were conducted by 2-dimensional polyacrylamid gel electrophoresis (2D-PAGE) and
label-free quantitative liquid chromatography - tandem mass spectrometry (LFQ LC-MS/MS). Controls for
2D 2D-PAGE and LFQ LC-MS/MS had bacteremia and excluded IE.
Results: Osteoprotegerin levels were significantly increased in IE patients compared with non-IE patients.
Fibulin-1 showed no difference. 2D-PAGE showed significant differences of 6 proteoforms: haptoglobin,
haptoglobin-related protein, α-2-macroglobulin, apolipoprotein A-I and ficolin-3. LFQ LC-MS/MS analysis
revealed significant level changes of 7 proteins: apolipoprotein L1, complement C1q subcomponent B and
C, leukocyte immunoglobulin-like receptor subfamily A member 3, neuropilin-2, multimerin-1 and
adiponectin.
Conclusions: The concentration changes in a set of proteoforms/proteins suggest that stress and
inflammation responses are perturbed in patients with IE compared to patients with bacteremia without
IE.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The incidence of infective endocarditis (IE) has increased during
the last decades to 1.7–6.2 cases per 100,000 population years
(Beynon et al., 2006; Bouza et al., 2001; Delahaye et al., 1995;
Griffin et al., 1985; Mylonakis and Calderwood, 2001). IE has a high
mortality, and despite treatment, the 12 month mortality reached
30% (Thuny et al., 2012a). The clinical challenge is to determine* Corresponding author at: Department of Biomedicine, Aarhus University,
Aarhus, Denmark, Ole Worms Allé 4, 8000 Aarhus C, Denmark.
E-mail address: bh@biomed.au.dk (B. Honoré).
https://doi.org/10.1016/j.ijid.2020.02.026
1201-9712/© 2020 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).whether a febrile patient with either a positive blood culture or a
suspected bacteremia also has IE. The diagnostic delay of IE can be
several weeks (Issa et al., 2003; Knudsen et al., 2009), increasing
the risk of death, heart failure, valve replacement and embolic
complications. The key diagnostic procedures are blood cultures
and transthoracic and transesophageal echocardiography. Bio-
markers aiding in the evaluation of patients with a low- or
intermediate risk of endocarditis would therefore be of great
clinical value.
At present, there are no biofluid biomarkers, which are used in
clinical practice to identify IE in patients with infection and/or
bacteremia (Snipsøyr et al., 2016). One problem with previous
studies has been the lack of proper control groups, i.e. patientsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
74 M.G. Snipsøyr et al. / International Journal of Infectious Diseases 96 (2020) 73–81with bacteremia and excluded endocarditis (Snipsøyr et al., 2016).
C-reactive protein (CRP) is a common biomarker for inflammation
but lacks sensitivity and specificity to distinguish between patients
with positive blood cultures with or without IE. Procalcitonin has
been suggested to differentiate between patients with and without
endocarditis (Mueller et al., 2004). However, data from our group
have shown that although procalcitonin is significantly higher in IE
patients than non-IE patients, it has a low specificity (Knudsen
et al., 2010).
The aim of the present study was to identify biomarkers of IE
in two ways. First, we investigated the potential of fibulin-1 and
osteoprotegerin (OPG) for the diagnosis of IE in a group of
patients suspected for IE. Fibulin-1 and OPG are markers of
cardiovascular disease (Hansen et al., 2013; Jono et al., 2002;
Kruger et al., 2014; Mogelvang et al., 2012; Palazzuoli et al.,
2008; Ren et al., 2008; Schoppet et al., 2003). Fibulin-1 is a
matrix protein and therefore also a structural part of the heart
valves (Argraves et al., 2009). OPG has been reported to be a
mediator of the calcification development of aortic stenosis
(Dahl et al., 2013), as well as possibly being involved in the
pathological processes and being a marker of mortality in atrial
fibrillation (Ueland et al., 2011). Second, we identified putative
biomarkers by proteomic investigation using two-dimensional
polyacrylamide gel electrophoresis (2D-PAGE) as well as label-
free quantitative liquid chromatography – tandem mass
spectrometry (LFQ LC-MS/MS) on serum samples from IE and
non-IE patients. We hypothesized that these proteomics
methods could detect proteins released from cardiac valve
tissue, inflammatory proteins or blood coagulation proteins in
order to find new putative markers of IE. In the proteomic
analyses we used a control group of patients with bacteremia
and with endocarditis excluded.
Materials and methods
Patients
The patients studied here were included in a previous study of
759 consecutive patients referred for echocardiographic examina-
tion on clinical suspicion of IE (Knudsen et al., 2010). Patients
underwent transthoracic and transesophageal echocardiography
and a 10 mL blood sample was obtained. Samples were centrifuged,
separated and frozen within 4 h. According to the Duke criteria
(Durack et al., 1994; Li et al., 2000) 112 patients had definite IE, 35
patients possible IE and 612 patients no IE. Among the patients
having definite and possible IE 118 (80%) had positive blood culture
while among those excluded for having IE 145 (24%) had positive
blood culture (Knudsen et al., 2010).
Among the 759 patients in the previous report, 63 patients had
insufficient serum for further analysis. Of the 696 patients included
here, 102 had definite IE, 31 had probable IE, while 563 had no IE.
The characteristics of the 696 patients included here are shown in
the Supplementary Table 1. Following fibulin-1 measurements, 7
patients lacked material for further analyzes, resulting in a total of
689 patients with OPG-measurements.
2D-PAGE and MS for protein identification were performed in
a subset of 12 patients with definite IE and damaged heart valves
verified by transesophageal echocardiography (TEE) and 12
matched patients with bacteremia and excluded IE diagnosis.
The characteristics are shown in the Supplementaty Table 2. All
12 patients in the study group as well as the 12 patients in the
control group had bacteremia. Patients are matched with respect
to age, gender, microbiological agent (4 patients with Staphylo-
coccus aureus, 2 patients with Enterococcus faecium and 6
patients with Streptococcus species), CRP and hemoglobin
measurement.ELISA for measurement of fibulin-1 and OPG
In all patients with sufficient amount of serum, we measured
fibulin-1 (n = 696) and OPG (n = 689) by established ELISA as
described previously (Cangemi et al., 2011; Hansen et al., 2013).
Differences between groups of patients were calculated using a
non-parametrical, two-tailed Mann-Whitney U-test. A p < 0.05
was considered significant.
Preparation of serum samples for proteomics
High abundant protein levels in serum is a large problem for
proteomic analysis since they may mask lower abundant proteins
(Farrah et al., 2011). We used two approaches to try to circumvent
this, immunodepletion of high abundant proteins and hexa-
peptide enrichment of low abundant proteins. Proteome PurifyTM
12 immunodepletion resin (R&D Systems, Minneapolis, MN, USA)
was used to deplete serum for 12 high abundant proteins,
essentially as described by the manufacturer. To 30 mL of serum
was added 1 mL of suspended immunodepletion resin and left for
30-60 minutes. on a rotary shaker. The resin was applied to Spin-X
filter units and centrifuged for 2 min. The proteins in the filtrate
were then precipitated using 5vol. of 100% acetone at 20 C
overnight. Samples were then centrifuged, washed with 50%
acetone, dried and dissolved in 2D-PAGE lysis buffer (9 M urea, 2%
(v/v) Triton X-100, 2% (v/v) immobilized pH gradient (IPG) buffer
(pH 4-7), 2% (w/v) dithiotreitol (DTT)). Rehydraton buffer (8 M
urea, 2% (wt/vol) CHAPS, 2% (vol/vol) IPG-buffer and 0.3% (wt/vol)
DTT) was added and the amount applied to the 2D gels was 200 mg.
For the ProteoMinerTM Protein Enrichment Kit (BioRad, Hercules,
CA, USA) 1 mL of serum samples were incubated with the beads as
described and finally eluted with rehydrated elution reagent (8 M
urea, 2% CHAPS, 5% acetic acid). Proteins were acetone precipitated
as above and dissolved in 2D-PAGE lysis buffer, rehydration buffer
was added and an amount of 250 mg was used for 2D-PAGE. For LFQ
LC-MS/MS 30 mg protein was mixed with reducing sample buffer
and separated by 1D-PAGE (Biorad TGX 4-16%). The electrophoresis
was stopped after migration of proteins approx. 1 cm into the gel
visualized by CBB. The gel plugs were excised and samples were
reduced at 60 C using 10 mM DTT for 30 min and alkylated using
55 mM iodoacetamide for 30 min. Two mg trypsin (Promega) was
added to each gel sample and incubated overnight. The peptides
were extracted by 50% acetronitrile and 0.1% formic acid followed
by vacuum evaporation. The samples were reconstituted in 2%
acetonitrile in 0.1% formic acid.
Protein separation by 2D-PAGE and identification by LC-MS/MS
The 2D-PAGE method has previously been described (Kamper
et al., 2011). In the first dimension, proteins were separated
according to their isoelectric point and in the second dimension
according to molecular mass. Proteins were stained using Sypro-
Ruby, where after they were visualized by ImageQuant LAS4010
(GE Healthcare, Buckinghamshire, UK). Subsequently, scanned gel
pictures were imported into and analyzed with PDQuest (BioRad,
Hercules, CA, USA) software for the Proteome PurifyTM analysis,
and Delta2D (DECODON, Greifswald, Germany) software for
ProteoMinerTM samples. The intensity of each spot was normalized
to the total intensity detected in the gel. Spots were matched
between gels and the mean relative intensity of each spot in each
group was calculated. The mean relative intensity of a spot in the IE
group divided by the mean relative intensity of the spot in the non-
IE group is listed as the fold change. Relative intensity changes of at
least 1.3-fold that were significant (p < 0.05, Mann–Whitney, U-
test) between the groups were detected. Finally, the spots were cut
out of the gel for protein identification as described previously
Table 1
OPG serum levels (ng/mL) measured in 689 patients belonging to different groups.a
Group (n)b Median (IQR)c (ng/mL) p-Value
Non-IE patients (557) 1.92 (1.38–2.90)
IE-patients (132) 2.40 (1.67–3.21) 0.002
Definite IEd (101) 2.57 (1.82–3.38) 0.0008
a All groups are compared to the non-IE group.
b n = number of patients.
c IQR = Interquartile range.
d According to the Duke Criteria.
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proteins were pretreated using acetonitrile and reduced with
dithiothreitol. Thereafter, iodoactemide was used to modify
cysteine residues in the proteins prior to cleavage with trypsin.
Eventually, peptide extraction was performed using one change of
Na4HCO3 and 3 changes of formic acid in acetonitrile. The
recovered proteins were then dried and subsequently dissolved
in 12 mL of buffer A (97.7% H20, 2% acetonitrile, and 0.3% formic
acid). Peptides were separated by nanoLC using an Easy nLC II
(Thermo Fisher Scientific, Waltham, MA, USA). MS/MS-analysis
was performed on a Q-TOF Premier (Waters, Milford, MA, USA).
With a flow rate of 300 nL/min, [Glu1]-Fibrinopeptide B (GFP), 300
fmol/L was used as lock mass. GFP was also used for calibration.
Masslynx v4.0 (Waters, Milford, MA, USA) was used to acquire MS
survey scans in the m/z-interval ranging from 450–1500. MS/MS
scans were acquired in the m/z-interval 50–1800. Eventually, raw
data were imported into ProteinLynx Global Server v2.3 (Waters,
Milford, MA, USA) and the data was used to search the Swiss-Prot
Database with the online version of the Mascot MS/MS Ion Search
facility (Matrix Science, Ltd., Boston, MA, USA, http://www.
matrixscience.com) (Perkins et al., 1999). These searches were
conducted with the following criteria: Doubly, triply and quadru-
ply charged ions with up to two missed cleavages, peptide mass
tolerance of 20 ppm, an MS/MS tolerance of 0.05 Da, and one fixed
modification, Carbamidomethyl (C). Peptides that were considered
as contaminants (cingulin, hornerin, filaggrin-2, BSA, trypsin and
keratins) were excluded, along with cross contaminated peptides
from previous samples. We manually assessed spectra of uncertain
identifications and excluded those with bad quality. To qualify as a
protein hit, there had to be a minimum of one significant peptide
identified (p < 0.05).
Direct protein identification and quantification by LFQ LC-MS/MS
Each sample was injected in duplicate into a Dionex RSLC
nanoUPLC system that was connected to a Quadrupole Orbitrap (Q
ExactivePlus) mass spectrometer equipped with a NanoSpray Flex
ion source (Thermo Scientific, Bremen, Germany). The flow
settings were 8 mL per min. for the sample loading onto a trapping
column, which was an Acclaim PepMap100 C18, 5 mm column
from Thermo Scientific. The nanoflow was set to 300 nL per min for
the peptide separation on the analytical column, which was a
50 cm Acclaim Pepmap RSLC, 75 mm inner diameter column
connected with nanoviper fittings. The nano-electrospray was
done using a Picotip ‘Silicatip’ emitter from New Objective. The LC
buffers were buffer A (99.9% water, 0.1% formic acid) and buffer B
(99.9% acetonitrile, 0.1% formic acid). The applied gradient was
from 10 to 45% buffer B over 35 min. The mass spectrometer was
operated in data-dependent acquisition mode. A full MS scan in the
mass range of 350 to 1850 m/z was acquired at a resolution of
70,000 with an AGC target of 3  106 and maximum fill time set to
250 ms. Instrument lock mass correction was applied using the
contaminant ion at 391.28429 m/z. In each cycle, the mass
spectrometer will trigger up to 12 MS/MS acquisitions on abundant
peptide precursor ions. The MS/MS scans were acquired with a
dynamic mass range at a resolution of 17,500, and with an AGC
target of 2  105 and max fill time of 60 ms. The precursor ions were
isolated using a quadrupole isolation window of 1.6 m/z and then
fragmented in the HCD trap with a normalized collision energy set
to 30. The under-fill ratio was set to 3.5% with the intensity
threshold at 1.2  105. Apex triggering was 3 to 10 s with charge and
exclude isotopes exclusion on, and dynamic exclusion set to 30 s.
Protein identification and quantification were done with Max-
Quant (v 1.5.5.1) (Tyanova et al., 2016a). The reviewed human
Swiss-Prot sequence database was downloaded on the 25th of
August 2016 from Uniprot. The label free quantification (LFQ)algorithm was activated. False discovery rates for PSM, protein and
site were each set at 1%. The LFQ minimum ratio count was set at 1.
MS/MS was required for LFQ comparisons. The match between
runs function was activated. Protein quantifications were per-
formed using unique and razor peptides, modified with oxidation
(M) or acetyl (protein N-terminal). Reversed sequences as decoys
and contaminant sequences have been added automatically by
MaxQuant. The results from MaxQuant were entered into Perseus
(v 1.5.4.1) (Tyanova et al., 2016b) where data was filtered and Log2
transformed. The protein amount in a sample was calculated from
the means of two technical replicates based on the normalized
peptide intensities belonging to the specific protein group. The
fold-changes of protein groups were calculated by taking the mean
in the IE group divided by the mean in the non-IE group. The
analysis was performed in steps requiring the proteins to be
detected in at least 70%, 80%, 90% and 100% of the samples. P-values
were calculated by a two-tailed t-test without further correction in
order not to increase the type 2 error with the risk of overlooking
putative markers.
Bioinformatic analysis
STRING version 11.0 (string-db.org) was used for bioinformatic
analysis (Szklarczyk et al., 2015) with the following proteins:
HPT_HUMAN (Haptoglobin), HPTR_HUMAN (Haptoglobin-related
protein), APOA1_HUMAN (Apolipoprotein A-I), A2MG_HUMAN
(Alpha-2-macroglobulin), FCN3_HUMAN (Ficolin-3), APOL1_HU-
MAN (Apolipoprotein L1), C1QB_HUMAN (Complement C1q
subcomponent subunit B), C1QC_HUMAN (complement C1q
subcomponent subunit C), NRP2_HUMAN (Neuropilin-2),
MMRN1_HUMAN (Multimerin-1), ADIPO_HUMAN (Adiponectin),
TR11B_HUMAN (OPG). LIRA3_HUMAN was not recognized by
STRING.
Results
Fibulin-1
The ELISA analysis for fibulin-1 did not show any significant
differences between groups investigated (data are given in the
Supplementary Figure 1). Thus, it seems that this biomarker has no
role in the diagnosis of IE.
Osteoprotegerin (OPG)
OPG was measured in all patients with sufficient serum
available, in total 689 patients (Table 1). OPG was significantly
increased in serum from IE-patients (n = 132) compared to the
control group of patients without IE (n = 557) (median 2.40 ng/mL
(range 1.67–3.21) vs. 1.92 ng/mL (1.38–2.90), respectively,
p = 0.002) (Table 1 and Supplementary Figure 2). When analyzing
patients with definite IE according to the Duke Criteria (n = 101),
we found a highly significant difference (2.57 ng/mL (1.82–3.38) vs.
1.92 ng/mL (1.38–2.90), p = 0.0008).
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confirmed IE according to the Duke Criteria compared to the non-IE
group gave an area under the curve (AUC) equal to 0.605 (95%
confidence interval [CI], 0.54–0.67). Sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV) for
different cut-off values are given in the Supplementary Table 3.
When comparing all IE patients with the non-IE group, the AUC
was 0.588.
Proteomic analysis
High abundant proteins in serum is a large problem for analysis
since they may mask lower abundant proteins (Farrah et al., 2011).
With the 2D-PAGE technique we used two different preparation
techniques in order to deplete the serum samples for high
abundant proteins. One used Proteome PurifyTM and the other used
ProteoMinerTM. In each case at least 550 spots were detected.
Figure 1 shows a representative sample immunodepleted for 12
proteins of high abundance using Proteome PurifyTM and Figure 2
shows a representative sample depleted for high abundant
proteins and enriched for low abundant proteins using ProteoMi-
nerTM. Thirteen protein spots differed significantly (p < 0.05) at
least 1.3-fold. Two spots were upregulated and eleven wereFigure 1. 2D-gel analysis showing differentially expressed protein spots between the IE g
PurifyTM 12 immunodepletion resin. All spots differing significantly (p < 0.05) at least 1
arrows and spot number. The identifications (haptoglobin, haptoglobin-related protein
Figure 2. 2D-gel analysis showing differentially expressed protein spots between the
ProteoMinerTM Protein Enrichment Kit. One spot differing significantly (p < 0.05) at leas
arrow and spot number. The identification (ficolin-3) is listed in Table 2.downregulated. The spots were excised from the gels and
subjected to LC-MS/MS identification as given in Table 2. Some
spots contained more than one protein identification, in which
case we cannot determine with certainty which protein is
responsible for the observed change. There were no upregulated
spots with only one identified protein. Six downregulated spots
with only one identified protein were found. They were haptoglo-
bin (2203), haptoglobin-related protein (2306), apolipoprotein A-I
(4004) and α-2-macroglobulin (5905 and 5910) shown in Figure 1
and ficolin-3 (445) shown in Figure 2. Spot numbers and fold
changes are listed in Table 2.
With the LFQ LC-MS/MS method we used the ProteoMinerTM kit
and detected 532 different protein groups combined in all samples.
Three hundred eleven were present in at least 70% of all samples in
each group, and amongst these we found 7 to be differentially
regulated as given in Figure 3 and Table 3. Significantly upregulated
protein groups were apolipoprotein L1 (APOL1), complement C1q
subcomponent subunits B and C (C1QB, C1QC) and leukocyte
immunoglobulin-like receptor subfamily A member 3 (LILRA3)
whileneuropilin-2(NRP2), multimerin-1(MMRN1) and adiponectin
(ADIPOQ) were downregulated. Fibulin-1 did not show any
significant differences between the groups in the proteomic analysis
in line with the ELISA measurements (not shown).roup and the control group (non-IE patients with bacteremia) based on the Proteome
.3-fold between the groups and containing one identified protein are marked with
, α-2-macroglobulin (2 proteoforms), apolipoprotein A–I) are listed in Table 2.
 IE group and the control group (non-IE patients with bacteremia) based on the
t 1.3-fold between the groups and containing one identified protein is marked with
Table 2
Identification of differentially expressed proteins (proteoforms) in patients with IE vs. non-IE by 2D-PAGE
SSP Identification Peptides Mascot Score Mr (Da) SwissProt Fold change (IE/non-IE)a p-Value
1207 Haptoglobin 4 284 45,177 HPT_HUMAN 0.53 0.045
Haptoglobin 1 82 38,457 HPT_PIG
Complement C4-A 2 134 192,664 CO4A_HUMAN
2203 Haptoglobin 8 510 45,177 HPT_HUMAN 0.51 0.033
Haptoglobin 1 84 38,457 HPT_PIG
Haptoglobin 1 57 38,577 HPT_MESAU
2306 Haptoglobin-related protein 1 58 39,005 HPTR_HUMAN 0.51 0.045
2502 Alpha-1-antitrypsin 3 184 46,707 A1AT_HUMAN 4.32 0.0032
Angiotensinogen 2 157 53,152 ANGT_HUMAN
Ig gamma-1 chain C region 1 69 36,083 IGHG1_HUMAN
Haptoglobin-related protein 1 58 39,005 HPTR_HUMAN
4004 Apolipoprotein A-I 7 519 30,759 APOA1_HUMAN 0.73 0.033
(1) APOA1_PONAB
4502 NIb 1.42 0.021
5903 NI 0.54 0.028
5905 Alpha-2-macroglobulin 1 81 163,188 A2MG_HUMAN 0.50 0.018
5908 NI 0.54 0.024
5910 Alpha-2-macroglobulin 2 129 163188 A2MG_HUMAN 0.52 0.018
161* Alpha-1-antitrypsin 6 494 46,878 A1AT_HUMAN 0.66 0.028
Vitronectin 4 271 55,069 VTNC_HUMAN
Angiotensinogen 3 193 53,438 ANGT_HUMAN
369* NI 0.41 0.004
445* Ficolin-3 1 42 33,395 FCN3_HUMAN 0.50 0.044
Proteins identified by using Proteome Purify except those indicated with * that were analysed using ProteoMinerTM.
a The intensity of each spot was normalized to the total intensity detected in the gel. Spots were matched between gels and the mean relative intensity of each spot in each
group was calculated. The mean relative intensity of a spot in the IE group divided by the mean relative intensity of the spot in the non-IE group is listed as the fold change.
b NI = not identified.
Figure 3. Vulcano plot of the 311 proteins detected in at least 70% of the samples in each group with the LFQ LC-MS/MS analysis based on the ProteoMinerTM Enrichment Kit.
The x-axis shows the fold-change (log2 scale) of the IE group versus the non-IE group and the y-axis shows log10 (p)-values from students t test. Seven proteins were
significantly differentially regulated (indicated with black spots). Identifications are given in Table 3.
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protein groups with significantly different levels in the IE versus the
non-IE group. A STRING bioinformatic analysis (Szklarczyk et al.,
2015) using the combined set of proteins observed to be perturbedfrom ELISA, 2D-PAGE and LFQ LC-MS/MS revealed that the proteins
are biologically related to a significantly higher degree than expected
(Figure 4). Ten of the proteins belong to the Biological Process
‘Response to stress’ and six belong to: ‘Immune response’.
Table 3
Identification of differentially expressed protein groups in patients with IE vs. non-IE by LFQ LC-MS/MS using ProteoMinerTM.
Identification Peptides Mr (kDa) SwissProt Fold change (IE/non-IE)a p-Value
Apolipoprotein L1 9 44.0 APOL1_HUMAN 1.90 0.004
Complement C1q subcomponent subunit B 7 26.7 C1QB_HUMAN 1.39 0.024
Complement C1q subcomponent subunit C 7 25.8 C1QC_HUMAN 1.39 0.028
Leukocyte immunoglobulin-like receptor subfamily A member 3*** 7 47.5 LIRA3_HUMAN 2.28 0.019
Neuropilin-2** 5 104.9 NRP2_HUMAN 0.50 0.049
Multimerin-1* 17 138.1 MMRN1_HUMAN 0.54 0.005
Adiponectin 6 26.4 ADIPO_HUMAN 0.50 0.045
The proteins were detected in 100% of samples, except when indicated, in at least 90% (*), 80% (**) and 70% (***) of all samples in each group.
a The fold-changes of the protein groups were calculated by taking the mean in the IE group divided by the mean in the non-IE group.
Figure 4. STRING analysis of the perturbed proteins found by proteomics. APOA1 (Apolipoprotein A–I), FCN3 (Ficolin-3), TNFRSF11B (OPG), C1QB (Complement C1q
subcomponent subunit B), APOL1 (Apolipoprotein L1), A2M (Alpha-2-macroglobulin), HP (Haptoglobin), HPR (Haptoglobin-related proteins), NRP2 (Neuropilin-2), C1QC
(Complement C1q subcomponent subunit C), MMRN1 (Multimerin-1), ADIPOQ (Adiponectin). There are 15 edges between the 12 proteins, which is higher than expected
(p < 1 1016). The proteins are biologically related to a significantly higher degree than expected for a random set of proteins. Ten of the perturbed proteins belong to the
Biological Process ‘Response to stress’ (red) and six to ‘Immune response’ (blue).
78 M.G. Snipsøyr et al. / International Journal of Infectious Diseases 96 (2020) 73–81Discussion
Patients and key findings
The aim of the present study was to identify putative
biomarkers for diagnosis of IE in an unselected population of
patients with suspected IE. The patients studied here were
recruited for a previous study consisting of 759 patients
(Knudsen et al., 2010), 147 patients with definite or possible
IE where 80% had positive blood cultures and 612 patients
excluded for having IE where 24% had positive blood cultures.
From the previous group it was possible to perform ELISA
measurements for fibulin-1 on 696 patents and for OPG on 689
patients. Furthermore, it was possible to perform proteomic
analyses on 24 patients, 12 IE patients and 12 non-IE patients, all
having bacteremia. In each group, 4 patients had Staphylococcus
aureus, 2 patients had Enterococcus faecium and 6 patients had
Streptococcus species. OPG levels were increased in IE patients
as compared with non-IE patients; however fibulin-1 did not
differentiate between groups, despite the fact that it is found in
heart valves and previously was found to be associated with
heart disease (Kruger et al., 2014). 2D-PAGE and LC-MS/MS
analysis identified a set of proteoforms or protein groups as
potential markers for IE.Osteoprotegerin (OPG)
OPG is a glycoprotein produced in different tissues, including
cardiovascular structures (Dhore et al., 2001; Nybo and Rasmussen,
2008; Schoppet et al., 2002). OPG is associated with atherosclerosis
(Hofbauer and Schoppet, 2004) and risk factors of coronary artery
disease (CAD) (Crisafulli et al., 2005; Hosbond et al., 2012; Jono et al.,
2002; Mogelvang et al., 2012; Palazzuoli et al., 2008; Ren et al., 2008;
Schoppet et al., 2003). In patients with aortic stenosis, OPG carries
prognostic information, possibly because of its role in the calcifica-
tion process (Dahl et al., 2013). Our OPG measurements were
significantly higher in IE patients. These findings may suggest that
OPG could be a biomarker to exclude IE in IE suspected patients.
Selected combinations of sensitivity, specificity, positive predictive
value and negative predictive value for OPG are given in the
Supplementary Table 3. The optimal cut-off value has to be defined.
In that context it is necessary to identify a cut-off value with either a
high sensitivity or a high negative predictive value. Also, its use in a
multi-marker strategy could be considered.
Proteomic analyses
We performed a number of proteomic analyses on 24 serum
samples using different preparation techniques and different
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essentially a top-down procedure quantifying the intact proteins
based on image analysis before identification while LFQ LC-MS/MS
is a bottom-up procedure where the proteins for technical reasons
are digested with trypsin before identification and quantification
by MS signal intensities. Thus, due to technical differences the
techniques are able to focus on different details. One of the obvious
strengths with 2D-PAGE is that it is able to separate a post-
translationally modified protein into several spots, even though
the specific modifications are unknown. In general, plasma
proteins migrate in 2D gels in several spots as a result of several
types of post-translational modifications, especially glycosyla-
tions. Thus, a concentration change in one spot may reflect a
concentration change in one specific proteoform (Smith and
Kelleher, 2013) encoded from the same gene and not necessarily a
large concentration change of the whole group of proteoforms
encoded. The 2D-PAGE analysis performed here revealed concen-
tration changes in a number of protein spots when comparing the
IE group with the non-IE group. Thus, we found significant
downregulation of proteoforms of haptoglobin, haptoglobin-
related protein, α-2-macroglobulin, apolipoprotein A-I and fico-
lin-3 in the IE group. The LFQ LC-MS/MS method, on the other
hand, does not distinguish between specific proteoforms of the
proteins as we have performed it here but rather handles all
proteoforms encoded from a gene as a protein group. With the LFQ
LC-MS/MS technique we did not find significant changes in these
proteins when analyzed as groups. However, with the latter
technique we detected significant downregulation of the protein
groups neuropilin-2, multimerin-1 and adiponectin while the
protein groups apolipoprotein L1, complement C1q subcomponent
subunits B and C and leukocyte immunoglobulin-like receptor
subfamily A member 3 were upregulated.
α-2 macroglobulin is involved in the hemostatic process.
Haptoglobin is known to bind hemoglobin. Ficolin-3 is known
to be a recognition molecule of the lectin pathway and is reported
to be associated with chronic heart failure severity and long-term
outcome (Garred et al., 2009; Prohaszka et al., 2013). A large part
of the proteins participate in the immune system. Further studies,
however, are needed to clarify the specific implications in IE. A
STRING bioinformatic analysis (Szklarczyk et al., 2015) using the
combined set of 13 proteoforms/protein groups revealed enrich-
ment of pathways related to stress and to the immune system.
Previous studies on IE and biomarkers have focused on
procalcitonin (Knudsen et al., 2010; Mueller et al., 2004; Watkin
et al., 2007; Yu et al., 2013), N-terminal pro-brain natriuretic
peptide (NT-proBNP) (Bjurman et al., 2012; Kahveci et al., 2007;
Shiue et al., 2010), cystatin C (Bjurman et al., 2012), troponins
(Purcell et al., 2008; Watkin et al., 2004), lipopolysaccharide-
binding protein (Vollmer et al., 2009; Watkin et al., 2007), S100A11
(Thuny et al., 2012b), aquaporin-9 (Thuny et al., 2012b) and E-
selectin (Soderquist et al., 1999). However, no studies have
previously investigated IE patients with an appropriate, compara-
ble control group, i.e., patients with bacteremia and excluded IE
(Snipsøyr et al., 2016) as in the present study. Secondly, OPG and
fibulin-1 have not previously been evaluated. A thrombotic
tendency in IE patients has been reported (Fukuda et al., 1982).
One of the findings in that study was decreased plasma level of
antithrombin III in IE-patients, contributing to a hyper coagulable
tendency. However, with our proteomic analysis using direct LC-
MS/MS, we could not detect a massive significant decrease in the
level of the protein group antithrombin III in the IE group (results
not shown). We found perturbations in the levels of other proteins,
i.e., a proteoform of α-2-macroglobulin and the protein group
multimerin-1 that might affect the coagulation process.Study limitations
Our hypothesis was to find biological markers originating from
damaged heart valves due to IE. However due to the small size of a
heart valve the concentration in the blood stream may be very low
and thereby difficult to detect. This could be circumvented by
performing analyses directly on the heart valves to detect changes
in proteins that subsequently might be detected in the blood
stream. Also, there are technical limitations to the study. The 2D-
PAGE technique may identify changes in a few proteoforms with
specific modifications while the LFQ LC-MS/MS analysis measures
groups of several proteoforms. The necessary efforts to deplete
samples for high abundant proteins may partly remove some lower
abundant attached proteins and the step that enriches for lower
abundant proteins (ProteoMinerTM) also levels out the concentra-
tion differences, thereby diminishing the observed differences.
Each of the techniques are capable of identifying only a subset of all
the proteins present, e.g., OPG was not identified by the direct LC-
MS/MS technique.
Conclusions
At present, no biomarker is being used in the diagnosis of IE, and
this is partly due to low specificity, but also some of the studies
require verification of results in larger cohorts before they can be
included in everyday clinical practice (Snipsøyr et al., 2016).
Finally, we want to stress that the markers given here are tentative
only and their utility in the clinical setting should be verified with
independent studies. The combined proteomic analyses performed
have detected a number of proteins that change in patients with IE,
ten that respond to stress and six belonging to the immune
response. Although these findings need to be verified, our
observations may indicate an impact on these systems. Further
studies are necessary to establish their specific roles. The
concentration of OPG was increased in IE patients. Its suitability
as a marker used alone is restricted due to low sensitivity and
specificity. However, its suitability used in combination with other
putative markers in a multi-marker strategy remains to be
clarified.
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